Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May-Jun;23(3):191-196.
doi: 10.1016/j.bjid.2019.05.006. Epub 2019 Jun 14.

Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review

João Paulo Telles  1 , Juliette Cieslinski  2 , Felipe Francisco Tuon  2
Affiliations

Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review

João Paulo Telles et al. Braz J Infect Dis. 2019 May-Jun.

Abstract

Backgroud: Daptomycin has been used in bone and joint infections (BJI) and prosthesis joint infections (PJI) considering spectrum of activity and biofilm penetration. However, the current experience is based on case reports, case series, cohorts, and international surveys. The aim of this systematic review was to evaluate studies about daptomycin treatment efficacy in BJI/PJI compared to other antibiotic regimens.

Methods: PubMed, LILACS, Scielo and Web of Science databases were searched for articles about daptomycin and treatment of BJI and PJI from inception to March 2018. Inclusion criteria were any published researches that included patients with BJI treated with daptomycin. Diagnosis of BJI was based on clinical, laboratory and radiological findings according to IDSA guidelines.

Results: From 5107 articles, 12 articles were included. Only three studies described the outcomes of patients with BJI treated with daptomycin with comparator regimen (vancomycin, teicoplanin and oxacillin). Studies presented large heterogeneity regarding device related infections, surgical procedures, and daptomycin regimens (varied from 4 mg/kg to 10 mg/kg). A total of 299 patients have been included in all studies (184 infections associated with orthopedic disposal and 115 osteomyelitis/septic arthritis). Two hundred and thirty-three patients were treated with daptomycin. The clinical cure rates on device related and non-device related infections (i.e. osteomyelitis) were 70% and 78%, respectively. Compared to all regimens evaluated, daptomycin group outcomes were non-inferior.

Conclusion: Although a randomized clinical trial is needed, this systematic review tends to support daptomycin usage for bone and joint infections.

Keywords: Arthritis; Daptomycin; Joint infection; Osteomyelitis; Staphylococcus aureus.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flowchart of selection process for daptomycin and BJI articles included in review.
See this image and copyright information in PMC

References

    1. Humphries R.M., Pollett S., Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev. 2013;26:759–780. - PMC - PubMed
    1. Stefani S., Chung D.R., Lindsay J.A., et al. Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents. 2012;39:273–282. - PubMed
    1. Liebowitz L.D. MRSA burden and interventions. Int J Antimicrob Agents. 2009;34 Suppl 3:S11–S13. - PubMed
    1. Nathwani D. Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin. J Antimicrob Chemother. 2009;64:447–453. - PubMed
    1. Osmon D.R., Berbari E.F., Berendt A.R., et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:e1–e25. - PubMed

Publication types

MeSH terms